| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc. | Cytisine - (ORCA-2) | Smoking cessation | NDA Filing | Ongoing | Oral | Anti-Addiction |
| Achieve Life Sciences Inc. | Cytisinicline - (ORCA-3) | Smoking cessation of cigarettes | PDUFA | Ongoing | Oral | Anti-Addiction |
| Achieve Life Sciences Inc. | Cytisine - (ORCA-2) | Smoking cessation | NDA Filing | Ongoing | Oral | Anti-Addiction |
| Achieve Life Sciences Inc. | Cytisinicline - (ORCA-OL) | Smoking cessation for current smokers or use nicotine e-cigarettes | NDA Filing | Enrollment Conclusion | Oral | Anti-Addiction |
| Achieve Life Sciences Inc. | Cytisinicline - (ORCA-V1) | E-cigarette & vape cessation | Phase 3 | Trial Planned | oral | Anti-Addiction |
| Aclaris Therapeutics Inc. | ATI-502 (ATI-50002-AA-201) - dose ranging | Alopecia areata | Phase 2 | Topical | Immunology | |
| Aclaris Therapeutics Inc. | ATI-502 (VITI-201 Topical) | Vitiligo | Phase 2 | Trial Discontinued | topical | N/A |
| Aclaris Therapeutics Inc. | ATI-502 (VITI-201 Topical) | Vitiligo | Phase 2 | Trial Discontinued | topical | N/A |